Perillaldehyde is the signature aldehydic marker of perilla and shiso oils in the AromaForge archive, where it often appears as the dominant constituent in perillaldehyde-type leaf distillates. The live evidence base is stronger than for many niche monoterpene aldehydes: identity and occurrence are straightforward, while preclinical studies report antifungal, inflammation-modulating, and biofilm-related activity. Safety framing is more nuanced because perillaldehyde is an alpha,beta-unsaturated aldehyde with historical genotoxicity discussion and fragrance restriction context, even though newer review and mutagenicity papers argue that in vivo mutagenic risk was not demonstrated under the tested conditions.
Aroma and practical use
- Use the recorded green, shiso-like, cumin-like, spicy, fresh descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Review the flagged use concerns across every contributing oil and the selected dilution.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2018 Journal of Agricultural and Food Chemistry paper reported that 100 mg/kg perillaldehyde mitigated colon damage and reduced inflammatory gene expression in a DSS-induced colitis mouse model, with parallel anti-inflammatory effects in macrophage cells.
A 2018 Journal of Agricultural and Food Chemistry paper reported that 100 mg/kg perillaldehyde mitigated colon damage and reduced inflammatory gene expression in a DSS-induced colitis mouse model, with parallel anti-inflammatory effects in macrophage cells.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2020 British Journal of Pharmacology-linked study reported that perillaldehyde inhibited Candida albicans biofilm formation, hyphal transition, and SAP gene expression, and reduced inflammatory burden in an experimental murine oropharyngeal candidiasis model.
A 2020 British Journal of Pharmacology-linked study reported that perillaldehyde inhibited Candida albicans biofilm formation, hyphal transition, and SAP gene expression, and reduced inflammatory burden in an experimental murine oropharyngeal candidiasis model.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2023 constituent-focused antifungal paper described perillaldehyde as having significant protective effects in tomato, grape, and postharvest fruit-pathogen settings, supporting broader antifungal screening interest beyond Candida models.
A 2023 constituent-focused antifungal paper described perillaldehyde as having significant protective effects in tomato, grape, and postharvest fruit-pathogen settings, supporting broader antifungal screening interest beyond Candida models.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2021 mutagenicity paper reported negative Ames findings for perillaldehyde and no increase in gene mutations in mouse liver, glandular stomach, or small intestine up to 1000 mg/kg/day in the in vivo assay used.
A 2021 mutagenicity paper reported negative Ames findings for perillaldehyde and no increase in gene mutations in mouse liver, glandular stomach, or small intestine up to 1000 mg/kg/day in the in vivo assay used.
This experimental finding does not establish benefit, dose or safety in people using this blend.
Use concerns and concentration limits
Sensitization concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
A recorded constituent reference, not a recommended oil dilution. Product category, source applicability and all contributing oils must be checked before use.
unverified reference · No source provenance attachedA modern review states that perillaldehyde is used as a flavor ingredient and is commonly described as GRAS, while also emphasizing that adverse-effect and toxicology interpretation still deserves caution.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Perillaldehyde remains safety-relevant in fragrance work because it is an alpha,beta-unsaturated aldehyde with historic mixed genotoxicity results and IFRA restriction context; that is more important for archive safety framing than broad wellness language.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
The local perilla-shiso-leaf oil record currently carries a very low finished-product maximum dermal figure derived from an IFRA certificate for the whole raw material rather than a neat-constituent topical limit.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
In a DSS-colitis mouse model and LPS-stimulated RAW264.7 macrophages, perillaldehyde was associated with reduced pro-inflammatory cytokine expression and JNK-linked cytokine regulation rather than NF-kB p65 suppression in that experiment.
In a DSS-colitis mouse model and LPS-stimulated RAW264.7 macrophages, perillaldehyde was associated with reduced pro-inflammatory cytokine expression and JNK-linked cytokine regulation rather than NF-kB p65 suppression in that experiment.
This experimental finding does not establish benefit, dose or safety in people using this blend.
In murine oropharyngeal candidiasis work, perillaldehyde was reported to inhibit Candida virulence traits and to reduce ROS accumulation, NLRP3 inflammasome assembly, and nuclear p65 transfer in host tissue.
In murine oropharyngeal candidiasis work, perillaldehyde was reported to inhibit Candida virulence traits and to reduce ROS accumulation, NLRP3 inflammasome assembly, and nuclear p65 transfer in host tissue.
This experimental finding does not establish benefit, dose or safety in people using this blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (5)
- This pass did not verify a clean, constituent-only modern leave-on dermal maximum for neat perillaldehyde from a primary IFRA or RIFM page that is directly readable without certificate indirection.
- Most direct benefit-style literature is still preclinical and often infection-model or inflammation-model specific, so the archive should avoid translating it into human therapeutic claims.
- CAS handling is inconsistent across local perilla oil files, with one record using 18031-40-8 and another using 2111-75-3; this constituent file follows PubChem's common perillaldehyde CAS 2111-75-3.
- The numeric dermal reference lacks source provenance; a verified flag alone is insufficient.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.